Emerging role of Janus kinase inhibitors in ulcerative colitis management

Ulcerative colitis (UC) is a chronic inflammatory bowel disease having high morbidity and a significant negative influence on patients' quality of life. Traditional medicinal strategies available, including amino salicylates, corticosteroids, and biologics, offer limited efficacy, safety, and durability of response. The advancement in small-molecule Janus kinase (JAK) inhibitors has introduced a novel, oral therapeutic option that targets intracellular signaling pathways implicated in UC pathogenesis. Tofacitinib is the first approved JAK inhibitor for the treatment of moderate-to-severe UC. This drug, despite offering promising efficacy, has various safety concerns, especially the occurrence of thromboembolic events. These adverse effects have stressed the development of more selective agents such as upadacitinib and filgotinib. This mini-review explores the current perspectives of JAK inhibitors in UC, particularly focusing on their mechanisms of action, safety profiles, clinical trial outcomes, and emerging strategies to enhance their use. This review also highlights future directions, including the potential of selective JAK1 inhibition and the role of personalized medicine in refining therapeutic decisions. Understanding the emerging place of JAK inhibitors within the UC treatment strategies offers excellent opportunities to increase patient care and long-term disease management.